Inventiva (IVA) Stock Forecast & Price Target

Compare

581 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IVA Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Inventiva

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IVA Stock 12 Month Forecast

Average Price Target

$17.86

▲(303.16% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Inventiva in the last 3 months. The average price target is $17.86 with a high forecast of $26.00 and a low forecast of $11.00. The average price target represents a 303.16% change from the last price of $4.43.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","27":"$27","6.75":"$6.75","13.5":"$13.5","20.25":"$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.75,13.5,20.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.3,5.969230769230769,7.638461538461538,9.307692307692307,10.976923076923075,12.646153846153844,14.315384615384616,15.984615384615385,17.653846153846153,19.323076923076922,20.99230769230769,22.66153846153846,24.33076923076923,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.3,5.343076923076923,6.386153846153846,7.429230769230768,8.472307692307691,9.515384615384615,10.558461538461538,11.60153846153846,12.644615384615385,13.687692307692306,14.73076923076923,15.773846153846154,16.816923076923075,{"y":17.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.3,4.815384615384615,5.3307692307692305,5.846153846153847,6.361538461538462,6.876923076923077,7.392307692307693,7.907692307692308,8.423076923076923,8.938461538461539,9.453846153846154,9.96923076923077,10.484615384615385,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.91,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$26.00

Average Price Target$17.86

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen Rahimi

Piper Sandler

$26

Buy

486.91%

Upside

Reiterated

11/25/25

Piper Sandler Keeps Their Buy Rating on Inventiva (IVA)

Seamus Fernandez

Guggenheim

$13→$11

Buy

148.31%

Upside

Reiterated

11/17/25

Inventiva price target lowered to $11 from $13 at GuggenheimInventiva price target lowered to $11 from $13 at Guggenheim

Andy Chen

Wolfe Research

$13

Buy

193.45%

Upside

Initiated

11/05/25

Inventiva initiated with an Outperform at Wolfe ResearchInventiva initiated with an Outperform at Wolfe Research

Edward Nash

Canaccord Genuity

$20

Buy

351.47%

Upside

Reiterated

10/29/25

Canaccord Genuity Remains a Buy on Inventiva (IVA)

Rami Katkhuda

LifeSci Capital

$14

Buy

216.03%

Upside

Reiterated

10/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PepGen Inc. (NASDAQ: PEPG) and Inventiva (NASDAQ: IVA)Invenva (Nasdaq: IVA) hosted a comprehensive Investor & Analyst Day yesterday, which highlighted laniﬁbranor’s mechanisc raonale and clinical data to date, baseline characteriscs for the fully enrolled Phase III NATiV3 trial (which are broadly comparable to the Phase IIb study), and KOL thoughts on the evolving treatment landscape in MASH. Overall, we connue to believe laniﬁbranor has the potenal to oﬀer best-in-disease ﬁbrosis beneﬁt (along with CV and metabolic beneﬁts) among oral agents approved/in development for MASH and that the ongoing pivotal study has a high probability of success in a large and growing commercial opportunity. Key takeaways from yesterday’s event include: MASH is an and Fibrosis.

Ananda Ghosh

H.C. Wainwright

$20→$24

Buy

441.76%

Upside

Reiterated

10/09/25

Buy Rating for Inventiva: Lanifibranor's Potential as a Foundational MASH Therapy

Annabel Samimy

Stifel Nicolaus

$17

Buy

283.75%

Upside

Reiterated

10/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Quest Diagnostics (NYSE: DGX) and Inventiva (NASDAQ: IVA)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

07/31/25

Inventiva (IVA) Receives a Buy from TD Cowen

Etzer Darout

Barclays

$12→$9

Buy

103.16%

Upside

Reiterated

04/04/25

Inventiva SA (IVA) PT Lowered to $9 at GuggenheimGuggenheim analyst Etzer Darout lowered the price target on Inventiva SA (NASDAQ: IVA) to $9.00 (from $12.00) while maintaining a Buy rating.

Ed Arce

Westpark Capital

$13

Buy

193.45%

Upside

Reiterated

04/03/25

Inventiva's Strategic Advancements and Financial Strength Bolster Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen Rahimi

Piper Sandler

$26

Buy

486.91%

Upside

Reiterated

11/25/25

Piper Sandler Keeps Their Buy Rating on Inventiva (IVA)

Seamus Fernandez

Guggenheim

$13→$11

Buy

148.31%

Upside

Reiterated

11/17/25

Inventiva price target lowered to $11 from $13 at GuggenheimInventiva price target lowered to $11 from $13 at Guggenheim

Andy Chen

Wolfe Research

$13

Buy

193.45%

Upside

Initiated

11/05/25

Inventiva initiated with an Outperform at Wolfe ResearchInventiva initiated with an Outperform at Wolfe Research

Edward Nash

Canaccord Genuity

$20

Buy

351.47%

Upside

Reiterated

10/29/25

Canaccord Genuity Remains a Buy on Inventiva (IVA)

Rami Katkhuda

LifeSci Capital

$14

Buy

216.03%

Upside

Reiterated

10/09/25

Ananda Ghosh

H.C. Wainwright

$20→$24

Buy

441.76%

Upside

Reiterated

10/09/25

Buy Rating for Inventiva: Lanifibranor's Potential as a Foundational MASH Therapy

Annabel Samimy

Stifel Nicolaus

$17

Buy

283.75%

Upside

Reiterated

10/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Quest Diagnostics (NYSE: DGX) and Inventiva (NASDAQ: IVA)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

07/31/25

Inventiva (IVA) Receives a Buy from TD Cowen

Etzer Darout

Barclays

$12→$9

Buy

103.16%

Upside

Reiterated

04/04/25

Inventiva SA (IVA) PT Lowered to $9 at GuggenheimGuggenheim analyst Etzer Darout lowered the price target on Inventiva SA (NASDAQ: IVA) to $9.00 (from $12.00) while maintaining a Buy rating.

Ed Arce

Westpark Capital

$13

Buy

193.45%

Upside

Reiterated

04/03/25

Inventiva's Strategic Advancements and Financial Strength Bolster Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Inventiva

1 Month

xxx

Success Rate

5/7 ratings generated profit

Average Return

+7.16%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +7.16% per trade.

3 Months

xxx

Success Rate

7/15 ratings generated profit

Average Return

-0.02%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of -0.02% per trade.

1 Year

Annabel SamimyStifel Nicolaus

Success Rate

8/15 ratings generated profit

Average Return

+29.83%

reiterated a buy rating 3 months ago

Copying Annabel Samimy's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +29.83% per trade.

2 Years

xxx

Success Rate

12/15 ratings generated profit

Average Return

+36.14%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +36.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IVA Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IVA has received 15 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. IVA average Analyst price target in the past 3 months is 17.86.

Each month's total comprises the sum of three months' worth of ratings.

IVA Financial Forecast

IVA Earnings Forecast

Next quarter’s earnings estimate for IVA is -$0.31 with a range of -$0.42 to -$0.18. The previous quarter’s EPS was -$1.62. IVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IVA has Performed in-line its overall industry.

IVA Sales Forecast

Next quarter’s sales forecast for IVA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $4.86M. IVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IVA has Performed in-line its overall industry.

IVA Stock Forecast FAQ

What is IVA’s average 12-month price target, according to analysts?

Based on analyst ratings, Inventiva’s 12-month average price target is 17.86.

What is IVA’s upside potential, based on the analysts’ average price target?

Inventiva has 303.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IVA a Buy, Sell or Hold?

Inventiva has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Inventiva’s price target?

The average price target for Inventiva is 17.86. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $26.00 ,the lowest forecast is $11.00. The average price target represents 303.16% Increase from the current price of $4.43.

What do analysts say about Inventiva?

Inventiva’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of IVA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Inventiva (IVA) Stock Forecast & Price Target

IVA Analyst Ratings

IVA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Inventiva

IVA Analyst Recommendation Trends

IVA Financial Forecast

IVA Earnings Forecast

IVA Sales Forecast

IVA Stock Forecast FAQ

Detailed List of Analyst Forecasts